Samuel John, M.D. Assistant Professor School Medical School Department Pediatrics You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Samuel John, M.D., is an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center and Attending physician in the Gill Center for Cancer and Blood Disorders at Children’s Medical Center in Dallas. He specializes in pediatric blood cancers, cellular therapy, and cancer immunotherapy. Dr. John earned his medical degree at Albany Medical College. He performed his residency in pediatrics at UT Southwestern and Children’s Medical Center, where he also completed a fellowship in pediatric hematology and oncology. He joined the UT Southwestern faculty in 2017. Dr. John serves as the CAR T-Cell Therapy Program leader for UT Southwestern and Children’s Medical Center. His clinical and research interests include cancer immunotherapies and cellular therapies, acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). He is the Principal Investigator at UT Southwestern for pediatric cell therapy clinical trials for leukemia and certain solid tumors. Dr. John’s joint research with Alec Zhang, Ph.D., has developed a novel CAR T-cell therapy for AML, which they are working to move into clinical trials. They are also developing CAR T-cells for other cancers, including both adult and pediatric solid tumors. Education Medical School Albany Medical College (2011) Residency UT Southwestern/Children's Medical Center (2014), Pediatrics Fellowship UT Southwestern/Children's Medical Center (2017), Pediatric Hematology/oncology Research Interest Acute myeloid leukemia Cell therapy Immunotherapy Publications Featured Publications A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. John S, Chen H, Deng M, Gui X, Wu G, Chen W, Li Z, Zhang N, An Z, Zhang CC Mol. Ther. 2018 Aug Low rate of subsequent malignant neoplasms following CAR T-cell therapy. Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard JD, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble A, Blood Adv 2022 Jul Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Lamble A, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard JD, Kovach AE, Wood BL, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN, Blood Adv 2022 Apr Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN, J Clin Oncol 2021 Nov JCO2101405 Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. Deng M, Chen H, Liu X, Huang R, He Y, Yoo B, Xie J, John S, Zhang N, An Z, Zhang CC, Antib Ther 2021 Jan 4 1 16-33 Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Churchill HRO, Fuda FS, Xu J, Deng M, Zhang CC, An Z, Zhang N, Chen P, Bergstrom C, Kansagra A, Collins R, John S, Koduru P, Chen W, Cytometry B Clin Cytom 2020 Sep Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells. Chen H, Chen Y, Deng M, John S, Gui X, Kansagra A, Chen W, Kim J, Lewis C, Wu G, Xie J, Zhang L, Huang R, Liu X, Arase H, Huang Y, Yu H, Luo W, Xia N, Zhang N, An Z, Zhang CC, J Immunother Cancer 2020 08 8 2 CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia. Pacenta HL, Laetsch TW, John S, Paediatr Drugs 2020 Feb 22 1 1-11 LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen GQ, Fu YX, Liao XC, An Z, Zheng J, Zhang N, Zhang CC Nature 2018 Oct 562 7728 605-609 Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors. Kang X, Kim J, Deng M, John S, Chen H, Wu G, Phan H, Zhang CC Cell Cycle 2015 Dec 0 Results 1-10 of 10 1 Honors & Awards Award for Clinical ExcellenceUT Southwestern/Childrens Medical Center (2014) Award for Clinical ExcellenceUT Southwestern/Childrens Medical Center (2013) Gold Humanism Honor Society Inductee (2011) Professional Associations/Affiliations American Academy of Pediatrics (2014) American Society of Clinical Oncology (2014) American Society of Hematology (2014) American Society of Pediatric Hematology- Oncology (2014) Childrens Oncology Group (2014)
